<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01088750</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000667369</org_study_id>
    <secondary_id>EURONET-PHL-LP1</secondary_id>
    <secondary_id>EUDRACT-2007-004092-19</secondary_id>
    <secondary_id>EU-21011</secondary_id>
    <nct_id>NCT01088750</nct_id>
  </id_info>
  <brief_title>Surgery Alone, Surgery With Cyclophosphamide, Vinblastine, and Prednisolone (CVP), or CVP Alone in Treating Young Patients With Stage IA or Stage IIA Nodular Lymphocyte-Predominant Hodgkin Lymphoma</brief_title>
  <official_title>First International Inter-Group Study for Nodular Lymphocyte-Predominant Hodgkin's Lymphoma in Children and Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Christine Mauz-Körholz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Deutsche Krebshilfe e.V., Bonn (Germany)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Euronet Worldwide</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Martin-Luther-Universität Halle-Wittenberg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, vinblastine, and
      prednisolone, work in different ways to stop the growth of cancer cells, either by killing
      the cells or by stopping them from dividing. Surgery to remove involved lymph nodes may be an
      effective treatment for young patients with nodular lymphocyte-predominant Hodgkin lymphoma.

      PURPOSE: This phase IV trial is continuing to study the side effects of giving surgery alone
      or giving surgery with cyclophosphamide, vinblastine, and prednisolone compared with giving
      cyclophosphamide, vinblastine, and prednisolone alone in treating young patients with stage
      IA or stage IIA nodular lymphocyte-predominant Hodgkin lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the 5-year event-free survival of children or adolescents with stage IA or IIA
           nodular lymphocyte-predominant Hodgkin lymphoma treated with surgery alone or with
           cyclophosphamide, vinblastine, and prednisolone.

      Secondary

        -  Determine if this regimen results in a decrease in overall survival rates, in
           significant upstaging at relapse, or increased rates of histological transformation in
           these patients.

      OUTLINE:

        -  Group 1 (patients with stage IA disease only): Patients undergo surgical resection of
           the involved lymph nodes. Patients who achieve complete resection then enter follow-up
           (watch and wait); patients who do not achieve complete resection enters group 2
           treatment.

        -  Group 2 (patients with stage IIA disease or incompletely resected stage IA disease):
           Patients receive cyclophosphamide, vinblastine, and prednisolone for 3 courses. Patients
           with good response enter follow-up (watch and wait). Patients without a good response
           are taken off protocol.

      After completion of study treatment, patients are followed-up periodically.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Significant upstaging at relapse defined as development of B-symptoms, extranodal disease, or relapse higher than stage II</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications of surgery</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>surgery alone</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>watch and wait strategy after complete resection of localised (e.g. Stage IA) nodular lymphocyte-predominant HL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CVP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 cycles of intensity-reduced, anthracycline-free chemotherapy (Cyclophosphamide, vinblastine and prednisone)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <arm_group_label>CVP</arm_group_label>
    <other_name>CYC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisolone</intervention_name>
    <arm_group_label>CVP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinblastine sulfate</intervention_name>
    <arm_group_label>CVP</arm_group_label>
    <other_name>VBL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>watchful waiting</intervention_name>
    <arm_group_label>surgery alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <arm_group_label>surgery alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of nodular lymphocyte-predominant Hodgkin lymphoma

               -  Stage IA or IIA disease

        PATIENT CHARACTERISTICS:

          -  Not specified

        PRIOR CONCURRENT THERAPY:

          -  No prior therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dieter Koerholz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitaetsklinikum Giessen und Marburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dieter Koerholz, MD</last_name>
    <email>dieter.koerholz@paediat.med.uni-giessen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christine Mauz-Koerholz, MD</last_name>
    <email>christine.mauz-koerholz@paediat.med.uni-giessen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitaetsklinikum Giessen-Marburg</name>
      <address>
        <city>Giessen</city>
        <zip>D-35385</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>0049-641-985-</phone>
      <phone_ext>57921</phone_ext>
      <email>dieter.koerholz@paediat.med.uni-giessen.de</email>
    </contact>
    <contact_backup>
      <last_name>Christine Mauz-Koerholz, MD</last_name>
      <email>christine.mauz-koerholz@paediat.med.uni-giessen.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2010</study_first_submitted>
  <study_first_submitted_qc>March 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2010</study_first_posted>
  <last_update_submitted>December 2, 2016</last_update_submitted>
  <last_update_submitted_qc>December 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Martin-Luther-Universität Halle-Wittenberg</investigator_affiliation>
    <investigator_full_name>Christine Mauz-Körholz</investigator_full_name>
    <investigator_title>Prof. Dr. Christine Mauz-Körholz</investigator_title>
  </responsible_party>
  <keyword>childhood nodular lymphocyte predominant Hodgkin lymphoma</keyword>
  <keyword>stage I childhood Hodgkin lymphoma</keyword>
  <keyword>stage II childhood Hodgkin lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

